FDA Approves PAPZIMEOS as First and Only Therapy for Recurrent Respiratory Papillomatosis (RRP) in Adults
Precigen, Inc., a biopharmaceutical company specializing in precision medicine, has announced that the US Food and Drug Administration (FDA) has approved PAPZIMEOS as the first and only FDA-approved therapy for treating adults with recurrent respiratory papillomatosis (RRP). This historic milestone marks a significant breakthrough in addressing the root cause of RRP, a rare and debilitating … Read more